Novo Nordisk is working with OpenAI on a broad deal that will use artificial intelligence to more quickly develop new medications as well as help train its workforce. Novo Nordisk’s U.S.-listed shares ...

Novo Nordisk is partnering with OpenAI to "bring new and better treatment options to patients faster," the Danish drugmaker said Tuesday. "Integrating AI in our everyday work gives us the ability to ...

Amid a major corporate overhaul, Novo Nordisk is pruning the ranks at its production facility in Bloomington, Indiana, which chips in on the blockbuster GLP-1 medications Ozempic and Wegovy. All told, ...

Novo Nordisk A/S’s Chairman Lars Rebien Sorensen faced intense scrutiny from investors at the company’s annual general meeting on Thursday, the first after his boardroom coup last year. Sorensen and ...

Novo Holdings saw its assets shrink by a third last year as part of the fallout of Novo Nordisk’s nosediving share price. The Copenhagen-based firm, which is the controlling shareholder of Novo ...

Novo Nordisk, the pharmaceutical company behind Ozempic, has received a warning letter from the U.S. Food and Drug Administration over issues with its procedures for reporting potential side effects ...

Novo Nordisk A/S plans to sell its weight-loss drugs on Hims & Hers Health Inc.’s platform, according to a person familiar with the matter, ending a highly public feud between the two companies that ...

Just when you think Novo Nordisk A/S (NVO) can't go any lower, it gets some more bad news, and the stock dips further. The stock already collapsed in 2025 as GLP-1 enthusiasm faded and political ...

Novo Nordisk announced Tuesday it will be slashing the list price of its blockbuster GLP-1 medications, Ozempic, Wegovy and Rybelsus, by up to 50 percent beginning next year. Starting on Jan. 1, 2027, ...

Novo Nordisk’s experimental weekly shot CagriSema was shown to lead to less dramatic weight loss compared to rival Lilly’s Tirzepatide, the drug behind Zepbound and Mounjaro, in an 84-week trial, Novo ...

Viewed from another perspective, though, it doesn't cost much more than it did back when the Ozempic craze began five years ago. Investors today have been given a second chance to buy, hold, and ...